Table 3

Descriptive characteristics for evaluated plasma markers
N Mean Median SD Min Max Wilcoxon’s p
NO (μmol/L)
Baseline samples 173 261.47 211.80 192.86 8.28 1,567.20 0.89
On-treatment samples* 51 237.09 227.10 140.68 42.69 606.70
OPN (ng/mL)
Baseline samples 173 98.68 62.56 89.29 23.12 512.00 0.002
On-treatment samples 51 75.42 54.72 76.32 25.44 507.52
TGF-β1(ng/mL)
Baseline samples 173 34.24 20.63 57.07 0.53 662.21 0.025
On-treatment samples 51 28.36 18.80 33.35 3.34 228.33
VEGF-A (pg/mL)
Baseline samples 172 122.54 57.85 190.33 15.60 1,601.31 <0.001
On-treatment samples 51 46.79 44.80 21.17 15.60 130.81

N, number; SD, standard deviation; Min, minimum level detected; Max, maximum level detected.

*On-treatment samples, at least 3 weeks after treatment initiation.

Pectasides et al.

Pectasides et al. BMC Cancer 2012 12:271   doi:10.1186/1471-2407-12-271

Open Data